Q2 2019 Cytokinetics Inc Earnings Call Transcript
Good afternoon and welcome, ladies and gentlemen, to the Cytokinetics Second Quarter 2019 Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)
I will now turn the call over to Diane Weiser, Cytokinetics' Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good afternoon, everyone and thank you for joining us today.
Robert Blum, our President and Chief Executive Officer, will kick off the call with introductory comments about the current state of our business. Then Fady Malik, our EVP of Research and Development, will provide updates on our cardiovascular program, including the Phase III development of omecamtiv mecarbil, our cardiac myosin activator, and the Phase I development of AMG 594, our cardiac troponin activator, both under our collaboration with Amgen as well as the development of CK-274, our wholly owned cardiac myosin inhibitor now proceeding from Phase I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |